SeaStar Medical Holding Corp

SeaStar Medical Holding Corp (Nasdaq: LMAO) is a medical device company developing selective cytopheresis technology aimed at treating acute organ dysfunction, including acute kidney injury. The company's public listing is tied to LMF Acquisition Opportunities Inc., a blank-check company sponsored by LMF Capital that completed its IPO in 2021. Operating in the healthcare and medical device sector, SeaStar Medical filed its annual Form 10-K with the SEC on April 6, 2022. The company's lead program centers on a Selective Cytopheresis Device designed to modulate immune response in critically ill patients. Sign up at SpacDesk for full filing history, sponsor profiles, and real-time SPAC market data.